title: [Effect of atorvastatin on pro-inflammatory status (in vivo and in vitro) in patients with essential hypertension and metabolic syndrome].
abstract: OBJECTIVE
  To study effect of atorvastatin on spontaneous production of cytokines and reactive oxygen species by mononuclear leukocytes of blood of hypertensive patients with metabolic syndrome in vivo and in vitro.
  
  
  METHODS
  We conducted an 8-week open prospective study on 36 patients with essential stage II hypertension associated with metabolic syndrome. Along with examination made in specialized cardiological clinic we assessed spontaneous production of cytokines and reactive oxygen species by blood mononuclear leukocytes during therapy with atorvastatin (in vivo). Dynamics of these parameters under the influence of atorvastatin on suspension of mononuclear leukocytes was also assessed in vitro.
  
  
  RESULTS
  Therapy with atorvastatin (20 to 40 mg/day) facilitated reduction of serum concentration of acute phase proteins (C-reactive protein and neopterin) and decrease of spontaneous production by blood mononuclear leukocytes of proinflammatory cytokines (interleukin [IL]-1β, IL-6 and tumor necrosis factor [TNF]-α) and reactive oxygen species. Dynamics of cytokine concentrations in supernatants of mononuclear leukocytes obtained after incubation of the cells with atorvastatin in vitro confirmed the assumption of direct inhibitory effect of this drug on spontaneous production of some proinflammatory cytokines (IL-6 and monocyte chemotactic protein-1). Absence of significant lowering of concentrations of other proinflammatory cytokines (IL-1β and TNF-α) and expression of reactive oxygen species in vitro evidenced for complex indirect effect of therapy with atorvastatin on their production.
authors.forename: I D
authors.initials: ID
authors.lastname: Bespalova
authors.forename: N V
authors.initials: NV
authors.lastname: Riazantseva
authors.forename: V V
authors.initials: VV
authors.lastname: Kaliuzhin
authors.forename: B Iu
authors.initials: BIu
authors.lastname: Murashev
authors.forename: I A
authors.initials: IA
authors.lastname: Osikhov
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Mediantsev
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069059:Atorvastatin; D016207:Cytokines / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D000075222:Essential Hypertension; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D007249:Inflammation / Q000097:blood / Q000473:pathology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008875:Middle Aged; D062072:Patient Acuity; D011446:Prospective Studies; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects; D017382:Reactive Oxygen Species / Q000097:blood*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D016207:Cytokines; D006538:Heptanoic Acids; D011758:Pyrroles; D017382:Reactive Oxygen Species; D000069059:Atorvastatin